Latest Period
Q1 2026
Security Snapshot
BRIGHT MINDS BIOSCIENCES INC. - Common Shares, no par value (DRUG) Institutional Ownership
CUSIP: 10919W405
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
93
Shares (Excl. Options)
9,188,351
Price
$72.97
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares, no par value
- Symbol
- DRUG on Nasdaq
- Shares outstanding
- 9,846,380
- Price per share
- $88.99
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 9,188,351
- Total reported value
- $670,257,375
- % of total 13F portfolios
- 0%
- Share change
- +2,601,377
- Value change
- +$189,168,166
- Number of holders
- 93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Shares, no par value is tracked under CUSIP 10919W405.
- 93 institutions reported positions in Q1 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 74 to 93 between Q4 2025 and Q1 2026.
- Reported value moved from $514,917,301 to $670,257,375.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 93 institutions filings for Q1 2026.
Security key
10919W405
Latest holder period
Q1 2026
13F holders
93
13D/G owners
10
CIK / CUSIP context first
Open Q1 2026 holders
DRUG full holder history
BRIGHT MINDS BIOSCIENCES INC. SEC filings
BRIGHT MINDS BIOSCIENCES INC. company facts
BRIGHT MINDS BIOSCIENCES INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 10919W405:
Significant Owners of BRIGHT MINDS BIOSCIENCES INC. - Common Shares, no par value (DRUG) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 13% | -12% | $107,305,270 | +$10,721,888 | 1,284,324 | +11% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Cormorant Asset Management, LP | 9.7% | -11% | $69,321,500 | -$7,977,883 | 950,000 | -10% | Cormorant Asset Management, LP | 28 Apr 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 5.2% | -20% | $42,163,090 | +$4,216,017 | 504,645 | +11% | Vivo Opportunity Fund Holdings, L.P. | 31 Mar 2026 |
| Vestal Point Capital, LP | 5% | $41,133,252 | 492,319 | Vestal Point Capital, LP | 31 Mar 2026 | |||
| PERCEPTIVE ADVISORS LLC | 4.6% | -28% | $40,171,019 | +$414,952 | 449,290 | +1% | Perceptive Advisors LLC | 31 Dec 2025 |
| Adage Capital Management, L.P. | 5.6% | $24,005,770 | 395,743 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 2.9% | $6,376,530 | 206,427 | RA Capital Management, L.P. | 31 Mar 2025 | |||
| Sio Capital Management, LLC | 2.7% | -65% | $11,571,744 | -$19,506,679 | 190,764 | -63% | Sio Capital Management, LLC | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 3% | $4,175,988 | 135,189 | Point72 Asset Management, L.P. | 31 Dec 2024 | |||
| Commodore Capital LP | 0.3% | -99% | $1,685,468 | -$43,019,532 | 18,851 | -96% | Commodore Capital LP | 31 Dec 2025 |
As of 31 Mar 2026, 93 institutional investors reported holding 9,188,351 shares of BRIGHT MINDS BIOSCIENCES INC. - Common Shares, no par value (DRUG). This represents 93% of the company’s total 9,846,380 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BRIGHT MINDS BIOSCIENCES INC. - Common Shares, no par value (DRUG) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 13% | 1,284,324 | +11% | 0.04% | $93,518,052 |
| Cormorant Asset Management, LP | 11% | 1,059,331 | 0% | 3.9% | $77,299,383 |
| BlackRock, Inc. | 6.3% | 621,933 | +58% | 0% | $45,382,452 |
| Vivo Capital, LLC | 5.7% | 557,172 | +11% | 3.4% | $40,656,841 |
| BRAIDWELL LP | 5.5% | 539,708 | +66% | 1.3% | $39,382,493 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5% | 495,743 | +25% | 0.06% | $36,174,367 |
| Vestal Point Capital, LP | 5% | 492,319 | 1% | $35,924,517 | |
| Driehaus Capital Management LLC | 4.4% | 432,515 | +60% | 0.23% | $31,560,620 |
| PERCEPTIVE ADVISORS LLC | 3.8% | 377,544 | -16% | 0.54% | $27,549,386 |
| Balyasny Asset Management L.P. | 3% | 297,158 | +32% | 0.04% | $21,683,619 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.9% | 283,000 | 0.24% | $20,650,510 | |
| RA CAPITAL MANAGEMENT, L.P. | 2.7% | 265,000 | 0.2% | $19,337,050 | |
| GREAT POINT PARTNERS LLC | 2.2% | 220,000 | 3.9% | $16,053,400 | |
| MPM BIOIMPACT LLC | 2.2% | 212,175 | -7.8% | 1.2% | $15,482,410 |
| Ikarian Capital, LLC | 1.7% | 166,647 | +4.5% | 1.7% | $12,160,232 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.4% | 136,677 | +899% | 0% | $9,973,321 |
| MORGAN STANLEY | 1.3% | 132,764 | +0.49% | 0% | $9,687,828 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 130,013 | +26% | 0.16% | $9,487,049 |
| SEVEN GRAND MANAGERS, LLC | 1.2% | 120,000 | +140% | 0.59% | $8,756,400 |
| ACUTA CAPITAL PARTNERS, LLC | 1.1% | 111,996 | +33% | 5.8% | $8,172,348 |
| STATE STREET CORP | 1.1% | 108,239 | +40% | 0% | $7,898,200 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.9% | 88,716 | +40% | 0% | $6,473,605 |
| Sio Capital Management, LLC | 0.87% | 86,083 | +5.1% | 0.91% | $6,281,477 |
| GOLDMAN SACHS GROUP INC | 0.76% | 74,369 | +53% | 0% | $5,426,706 |
| B Group, Inc. | 0.69% | 67,500 | 3.7% | $4,925,475 |
Institutional Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Shares, no par value (DRUG) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 9,188,351 | $670,257,375 | +$189,168,166 | $72.97 | 93 |
| 2025 Q4 | 6,590,203 | $514,917,301 | +$43,333,109 | $78.04 | 74 |
| 2025 Q3 | 6,040,789 | $366,118,700 | +$48,861,748 | $60.66 | 63 |
| 2025 Q2 | 5,234,387 | $136,973,710 | -$2,453,899 | $26.11 | 46 |
| 2025 Q1 | 5,217,399 | $188,361,504 | +$11,625,261 | $36.07 | 34 |
| 2024 Q4 | 4,897,032 | $176,406,965 | +$167,324,812 | $36.02 | 31 |
| 2024 Q3 | 191,547 | $229,810 | -$6,160 | $1.17 | 6 |
| 2024 Q2 | 197,030 | $207,191 | -$19,280 | $1.05 | 5 |
| 2024 Q1 | 213,375 | $255,563 | -$27,190 | $1.20 | 7 |
| 2023 Q4 | 228,082 | $329,806 | +$48,212 | $1.43 | 7 |
| 2023 Q3 | 194,505 | $309,171 | +$309,171 | $1.60 | 5 |